I’m back with another semi-regular column tracking the ups and downs in small-cap biotech. Today, I take a look at Bio-Path Holdings (BPTH) and CytoDyn (CYDY). Hint: Red flags hoisted on both. As a reminder, I’m taking requests for companies to cover, so reach out to me on Twitter (DMs are open), email, or in the comment section of the column.
Shares of Bio-Path Holdings soared an astounding 700 percent over the past two trading sessions. But the company-issued press release that triggered the stock surge omitted some sobering information about its experimental blood cancer drug. Was that misleading? I think it was. Bio-Path’s CEO disagrees. I spoke to him by phone on Thursday night.
Let’s break down this crazy Bio-Path story, starting with the incredible stock volatility — an eightfold jump in the share price in two trading sessions.
About the Author Reprints
